pyrroles has been researched along with losartan in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cachofeiro, V; Nasjletti, A; Sakakibara, T | 1 |
| Liebson, PR | 1 |
| Daskalopoulou, SS; Elisaf, M; Mikhailidis, DP; Tzovaras, V | 1 |
| Ali, SA; Arayne, MS; Haroon, U; Qureshi, F; Sultana, N | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Georgescu, EF; Georgescu, M | 1 |
| Chen, P; Edwards, PA; Guo, AM; Scicli, AG; Trick, G | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Duda, M; Maczewska, J; Maczewski, M | 1 |
| Guo, J; Hu, Z; Wang, Q; Wu, J; Wu, X; Xu, J; Yin, Z | 1 |
| Lin, P; Xie, H; Xie, L; Xu, C | 1 |
| Gassman, J; Gipson, D; Greene, T; Joy, M; Pinsk, M; Savin, V; Somers, M; Trachtman, H; Vento, S; Wickman, L | 1 |
| Babaoglu, MO; Bozkurt, A; Kilicarslan, A; Sain-Guven, G; Yardimci, Y; Yasar, U | 1 |
| Drevenšek, G; Janić, M; Jerin, A; Lunder, M; Sabovič, M; Skitek, M; Ziberna, L | 1 |
| Dinarvand, B; Dinarvand, P; Farhadian, S; Jalali, A; Sanaei-Rad, P; Seyedjafari, E; Shafiee, A; Soleimani, M | 1 |
| El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A | 1 |
| Budhiraja, RD; Sharma, S; Tyagi, S | 1 |
| Drevenšek, G; Janić, M; Lunder, M; Šabovič, M; Žiberna, L | 1 |
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M | 1 |
| Asiabi, H; Mehraban, JA; Shamsayei, M; Yamini, Y | 1 |
| Guan, Y; Kobara, H; Kobori, H; Li, L; Masaki, T; Morishita, A; Nakano, D; Nishiyama, A | 1 |
1 review(s) available for pyrroles and losartan
| Article | Year |
|---|---|
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Losartan; Pyrroles; Uric Acid | 2005 |
3 trial(s) available for pyrroles and losartan
| Article | Year |
|---|---|
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholagogues and Choleretics; Fatty Liver; Female; Hematologic Agents; Hepatitis; Heptanoic Acids; Humans; Losartan; Male; Middle Aged; Pentoxifylline; Pyrroles; Treatment Outcome; Ursodeoxycholic Acid | 2007 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Follow-Up Studies; Galactose; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Humans; Infant; Lisinopril; Losartan; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2011 |
17 other study(ies) available for pyrroles and losartan
| Article | Year |
|---|---|
Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine; Biphenyl Compounds; Blood Pressure; Captopril; Hypertension; Imidazoles; Kinins; Losartan; Male; Nitric Oxide; omega-N-Methylarginine; Pyrroles; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles | 1992 |
In vitro availability of atorvastatin in presence of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Drug Interactions; Heptanoic Acids; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Models, Chemical; Pyrroles; Solubility; Spectrophotometry, Ultraviolet; Temperature; Time Factors | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis.
Topics: Acetophenones; Acetylcysteine; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Imidazoles; Indoles; Leukostasis; Losartan; Male; NADPH Oxidases; Pyridines; Pyrroles; Rats; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Retinal Diseases; Vascular Endothelial Growth Factor A; Vasoconstrictor Agents | 2007 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Echocardiography; Heptanoic Acids; Hypercholesterolemia; Losartan; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Cattle; Cerebellum; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Injections, Intravenous; Liver; Losartan; Male; Protein Binding; Pyrroles; Rabbits; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Time Factors; Triazoles; Vasoconstriction | 2008 |
Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Atorvastatin; Base Sequence; Calcium Channels, L-Type; Disease Models, Animal; DNA Primers; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inositol 1,4,5-Trisphosphate Receptors; Losartan; Male; Monocrotaline; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2010 |
Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C9; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Losartan; Male; Middle Aged; Pyrroles; Retrospective Studies | 2011 |
Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atorvastatin; Biomarkers; Blood Pressure; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Myocardial Reperfusion Injury; Perfusion; Pyrroles; Rats; Rats, Wistar; Time Factors; Vasodilation; Vasodilator Agents | 2013 |
Novel approach to reduce postsurgical adhesions to a minimum: administration of losartan plus atorvastatin intraperitoneally.
Topics: Angiotensin Receptor Antagonists; Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Losartan; Male; Mice; Plasminogen Activator Inhibitor 1; Postoperative Complications; Pyrroles; RNA, Messenger; Tissue Adhesions; Tissue Plasminogen Activator; Transforming Growth Factor beta1 | 2013 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Atorvastatin; Blood Pressure; Desoxycorticosterone; Endothelium, Vascular; Female; Glutathione; Heptanoic Acids; Hypertension; Losartan; Male; Nitrates; Nitrites; Phosphoinositide-3 Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; Thiazolidinediones | 2012 |
A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts.
Topics: Analysis of Variance; Animals; Aorta; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Losartan; Male; Muscle Relaxation; Pyrroles; Rats; Rats, Wistar; Regional Blood Flow; Reperfusion Injury; Treatment Outcome | 2012 |
Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atorvastatin; Drug Therapy, Combination; Female; Gene Expression Regulation; Heptanoic Acids; Losartan; Male; Organ Culture Techniques; Pyrroles; Random Allocation; Rats; Rats, Wistar; Treatment Outcome; Vasodilation | 2013 |
A nanocomposite prepared from a polypyrrole deep eutectic solvent and coated onto the inner surface of a steel capillary for electrochemically controlled microextraction of acidic drugs such as losartan.
Topics: Electrochemical Techniques; Electrodes; Limit of Detection; Losartan; Nanocomposites; Polymers; Pyrroles; Solid Phase Microextraction; Steel | 2018 |
Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Kidney Function Tests; Losartan; Male; Mineralocorticoid Receptor Antagonists; Pyrroles; Rats; Rats, Inbred Dahl; Renin; Sodium Chloride, Dietary; Sulfones | 2019 |